Literature DB >> 15801966

Gene expression profiling in polycythaemia vera: overexpression of transcription factor NF-E2.

Philipp S Goerttler1, Clemens Kreutz, Johannes Donauer, Daniel Faller, Thomas Maiwald, Edith März, Brigitta Rumberger, Titus Sparna, Annette Schmitt-Gräff, Jochen Wilpert, Jens Timmer, Gerd Walz, Heike L Pahl.   

Abstract

Summary The molecular aetiology of polycythaemia vera (PV) remains unknown and the differential diagnosis between PV and secondary erythrocytosis (SE) can be challenging. Gene expression profiling can identify candidates involved in the pathophysiology of PV and generate a molecular signature to aid in diagnosis. We thus performed cDNA microarray analysis on 40 PV and 12 SE patients. Two independent data sets were obtained: using a two-step training/validation design, a set of 64 genes (class predictors) was determined, which correctly discriminated PV from SE patients. Separately 253 genes were identified to be upregulated and 391 downregulated more than 1.5-fold in PV compared with healthy controls (P < 0.01). Of the genes overexpressed in PV, 27 contained Sp1 sites: we therefore propose that altered activity of Sp1-like transcription factors may contribute to the molecular aetiology of PV. One Sp1 target, the transcription factor NF-E2 [nuclear factor (erythroid-derived 2)], is overexpressed 2- to 40-fold in PV patients. In PV bone marrow, NF-E2 is overexpressed in megakaryocytes, erythroid and granulocytic precursors. It has been shown that overexpression of NF-E2 leads to the development of erythropoietin-independent erythroid colonies and that ectopic NF-E2 expression can reprogram monocytic cells towards erythroid and megakaryocytic differentiation. Transcription factor concentration may thus control lineage commitment. We therefore propose that elevated concentrations of NF-E2 in PV patients lead to an overproduction of erythroid and, in some patients, megakaryocytic cells/platelets. In this model, the level of NF-E2 overexpression determines both the severity of erythrocytosis and the concurrent presence or absence of thrombocytosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15801966     DOI: 10.1111/j.1365-2141.2005.05416.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  44 in total

1.  Efficacy of vorinostat in a murine model of polycythemia vera.

Authors:  Hajime Akada; Saeko Akada; Ajeet Gajra; Alicia Bair; Stephen Graziano; Robert E Hutchison; Golam Mohi
Journal:  Blood       Date:  2012-03-09       Impact factor: 22.113

Review 2.  Regulation and function of the NFE2 transcription factor in hematopoietic and non-hematopoietic cells.

Authors:  Jadwiga J Gasiorek; Volker Blank
Journal:  Cell Mol Life Sci       Date:  2015-02-27       Impact factor: 9.261

3.  AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2.

Authors:  Wei Wang; Sven Schwemmers; Elizabeth O Hexner; Heike L Pahl
Journal:  Blood       Date:  2010-03-25       Impact factor: 22.113

Review 4.  Platelet genomics and proteomics in human health and disease.

Authors:  Iain C Macaulay; Philippa Carr; Arief Gusnanto; Willem H Ouwehand; Des Fitzgerald; Nicholas A Watkins
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

Review 5.  Proteomic approaches to dissect platelet function: Half the story.

Authors:  Dmitri V Gnatenko; Peter L Perrotta; Wadie F Bahou
Journal:  Blood       Date:  2006-08-22       Impact factor: 22.113

Review 6.  Erythro-megakaryocytic transcription factors associated with hereditary anemia.

Authors:  John D Crispino; Mitchell J Weiss
Journal:  Blood       Date:  2014-03-20       Impact factor: 22.113

7.  A3669G polymorphism of glucocorticoid receptor is a susceptibility allele for primary myelofibrosis and contributes to phenotypic diversity and blast transformation.

Authors:  Valentina Poletto; Vittorio Rosti; Laura Villani; Paolo Catarsi; Adriana Carolei; Rita Campanelli; Margherita Massa; Myriam Martinetti; Gianluca Viarengo; Alberto Malovini; Anna Rita Migliaccio; Giovanni Barosi
Journal:  Blood       Date:  2012-08-09       Impact factor: 22.113

8.  Enhanced calreticulin expression in red cells of polycythemia vera patients harboring the JAK2V617F mutation.

Authors:  Mégane Brusson; Sylvie Cochet; Marjorie Leduc; François Guillonneau; Patrick Mayeux; Thierry Peyrard; Christine Chomienne; Caroline Le Van Kim; Bruno Cassinat; Jean-Jacques Kiladjian; Wassim El Nemer
Journal:  Haematologica       Date:  2017-04-06       Impact factor: 9.941

9.  JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling.

Authors:  Sven Schwemmers; Britta Will; Cornelius F Waller; Khadija Abdulkarim; Peter Johansson; Björn Andreasson; Heike L Pahl
Journal:  Exp Hematol       Date:  2007-08-30       Impact factor: 3.084

10.  Gene and microRNA analysis of neutrophils from patients with polycythemia vera and essential thrombocytosis: down-regulation of micro RNA-1 and -133a.

Authors:  Stefanie Slezak; Ping Jin; Lorraine Caruccio; Jiaqiang Ren; Michael Bennett; Nausheen Zia; Sharon Adams; Ena Wang; Joao Ascensao; Geraldine Schechter; David Stroncek
Journal:  J Transl Med       Date:  2009-06-04       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.